alexander_hardy

Alexander Hardy returns to Genentech as new CEO

pharmafile | January 28, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Genentech, Roche, appointment, pharma 

Genetech, the biotech subsidiary of Swiss firm Roche, has named its new CEO, revealing that Alexander Hardy will be returning to the company to lead its operations.

Hardy originally joined Genentech in 2005, and during his time with the company he has held a number of senior management roles, including the management of patient access services and commercial operations across a range of disciplines such as influenza, neuroscience, and HER2-positive breast cancer.

He currently serves as Head of Product Strategy, previously becoming head of Asia Pacific operations in 2014. Hardy will assume the role on 1 March this year, succeeding current CEO Bill Anderson, who himself became Chief Executive of Roche on 1 January.  

“We’re delighted to welcome Alexander back to Genentech as Chief Executive Officer,” remarked Anderson. “He brings significant global expertise in the delivery of breakthrough medicines and a deep connection to the company culture. I look forward to seeing Genentech’s scientific excellence, employee experience and dedication to patients thrive under his leadership.”

Matt Fellows

Related Content

FDA approves Roche’s HPV self-collection screening option

Roche has announced that the US Food and Drug Administration (FDA) has approved its human …

Roche’s Alecensa approved by FDA as lung cancer treatment

Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …

Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment

Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …

Latest content